Mass spectrometry reveals that oxysterols are secreted from non-alcoholic fatty liver disease induced organoids
The Journal of Steroid Biochemistry and Molecular Biology · 2023-09 · 232 · 106355
DOI: 10.1016/j.jsbmb.2023.106355 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Steroid Biochemistry and Molecular Biology, 2023-09. Verfasst von Kristina Sæterdal Kømurcu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Oslo, P.O. Box 1033 Blindern, 0315 Oslo, Norway; Hybrid Technology Hub - Centre of Excellence, Institute of Ba…. Hauptthemen laut MEDLINE: Oxysterols, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norges Forskningsråd, Olav Thon Stiftelsen.
Abstract (Originalsprache)
Oxysterols are potential biomarkers for liver metabolism that are altered under disease conditions such as non-alcoholic fatty liver disease (NAFLD). We here apply sterolomics to organoids used for disease modeling of NAFLD. Using liquid chromatography-mass spectrometry with on-line sample clean-up and enrichment, we establish that liver organoids produce and secrete oxysterols. We find elevated levels of 26-hydroxycholesterol, an LXR agonist and the first oxysterol in the acidic bile acid synthesis, in medium from steatotic liver organoids compared to untreated organoids. Other upregulated sterols in medium from steatotic liver organoids are dihydroxycholesterols, such as 7α,26-dihydroxycholesterol, and 7α,25-dihydroxycholesterol. Through 26-hydroxycholesterol exposure to human stem cell-derived hepatic stellate cells, we observe a trend of expressional downregulation of the pro-inflammatory cytokine CCL2, suggesting a protective role of 26-hydroxycholesterol during early-phased NAFLD disease development. Our findings support the possibility of oxysterols serving as NAFLD indicators, demonstrating the usefulness of combining organoids and mass spectrometry for disease modeling and biomarker studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Oslo, P.O. Box 1033 Blindern, 0315 Oslo, Norway; Hybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1110 Blindern, 0317…
- Hybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1110 Blindern, 0317 Oslo, Norway; Department of Immunology and Transfusion Medicine, Oslo University Hospit…
- School of Food Science and Nutrition, University of Leeds, Leeds LS2 9JT, United Kingdom.
- Hybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1110 Blindern, 0317 Oslo, Norway.
Förderung
- Norges Forskningsråd
- Olav Thon Stiftelsen
Zitieren
APA
Kømurcu, K. S., Wilhelmsen, I., Thorne, J. L., Krauss, S., Wilson, S. R., Aizenshtadt, A., & Røberg-Larsen, H. (2023). Mass spectrometry reveals that oxysterols are secreted from non-alcoholic fatty liver disease induced organoids. The Journal of Steroid Biochemistry and Molecular Biology, 232, 106355. https://doi.org/10.1016/j.jsbmb.2023.106355
Vancouver
Kømurcu KS, Wilhelmsen I, Thorne JL, Krauss S, Wilson SR, Aizenshtadt A, et al. Mass spectrometry reveals that oxysterols are secreted from non-alcoholic fatty liver disease induced organoids. The Journal of Steroid Biochemistry and Molecular Biology. 2023;232:106355. doi:10.1016/j.jsbmb.2023.106355
BibTeX
@article{Kmurcu2023,
author = {Kømurcu, Kristina Sæterdal and Wilhelmsen, Ingrid and Thorne, James L and Krauss, Stefan and Wilson, Steven Ray and Aizenshtadt, Aleksandra and Røberg-Larsen, Hanne},
title = {Mass spectrometry reveals that oxysterols are secreted from non-alcoholic fatty liver disease induced organoids},
journal = {The Journal of Steroid Biochemistry and Molecular Biology},
year = {2023},
volume = {232},
pages = {106355},
doi = {10.1016/j.jsbmb.2023.106355}
}
EUVIMED